Area of research
Molecular Biology · Nephrology
Research interest
Research interests include Amyloidosis: Diagnosis, Treatment, Outcomes, Parathyroid Disorders and Treatments, Alzheimer's disease research and treatments, and Dermatological and Skeletal Disorders.
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis
Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)
A Consolidated Overview Of 14 Years Of Global Data From The Transthyretin Amyloidosis Outcomes Survey
Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis